Ad Hoc Afatinib in an Eldery Lung Cancer Patient with EGFR Exon 19 Deletion L747-A750>P

Annalisa Guida; Valentina Tassi; Francesco Facchinetti; Giovanni Marchetti; Cecilia Caprera; Mark Ragusa; Marcello Tiseo; Sergio Bracarda

doi:10.5603/ARM.a2022.0034

You are currently viewing a new version of our website. To view the old version click .

Advances in Respiratory Medicine is published by MDPI from Volume 90 Issue 4 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Via Medica.

Letter

17 May 2022

Ad Hoc Afatinib in an Eldery Lung Cancer Patient with EGFR Exon 19 Deletion L747-A750>P

and

Medical Oncology, Azienda Ospedaliera Santa Maria, Terni, Italy

Thoracic Surgery Unit, Azienda Ospedaliera Santa Maria, via Tristano di Joannucci, 05100 Terni, Italy

Université Paris-Saclay, Institut Gustave Roussy, Inserm, Biomarqueurs prédictifs et nouvelles stratégies thérapeutiques en oncologie, Villejuif, France

⁴

Division of Pathology, Azienda Ospedaliera Santa Maria, Terni, Italy

Adv. Respir. Med.2022, 90(3), 234-235;https://doi.org/10.5603/ARM.a2022.0034

Version Notes

Order Reprints

Excerpt

Note: In lieu of an abstract, this is an excerpt from the first page.

Approximately 10–20% of patients with non–small-cell lung cancer (NSCLC) harbor an epidermal growth factor receptor (EGFR) [...]

Article Metrics

Citations

Article Access Statistics

Journal Statistics

Multiple requests from the same IP address are counted as one view.

Should a Prescription Database Be Used to Search Uncontrolled Severe Asthmatics?

Publisher’s Note: A New Chapter for Advances in Respiratory Medicine—Continued Publication by MDPI